Literature DB >> 10627530

Characterization of the trans-activation properties of equine herpesvirus 1 EICP0 protein.

D E Bowles1, S K Kim, D J O'Callaghan.   

Abstract

The EICP0 protein of equine herpesvirus 1 (EHV-1) is an early, viral regulatory protein that independently trans-activates EHV-1 immediate-early (IE), early, gamma1 late, and gamma2 late promoters. To assess whether this powerful trans-activator functions in conjunction with three other EHV-1 regulatory proteins to activate expression of the various classes of viral promoters, transient cotransfection assays were performed in which effector plasmids expressing the EICP22, EICP27, and IE proteins were used either singly or in combination with an EICP0 effector construct. These analyses revealed that (i) independently, the EICP0 and IE proteins are powerful trans-activators but do not function synergistically, (ii) the IE protein inhibits the ability of the EICP0 protein to trans-activate the IE, gamma1 late, and gamma2 late promoters, (iii) the EICP22 and EICP0 proteins do not function together to significantly trans-activate any EHV-1 promoter, and (iv) the EICP27 and EICP0 proteins function synergistically to trans-activate the early and gamma1 late promoters. A panel of EICP0 truncation and deletion mutant plasmids was generated and used in experiments to define the domains of the 419-amino-acid (aa) EICP0 protein that are important for the trans-activation of each class of EHV-1 promoters. These studies revealed that (i) carboxy-terminal truncation mutants of the EICP0 protein exhibited a progressive loss of trans-activating ability as increasing portions of the carboxy terminus were removed, (ii) the amino terminus of the EICP0 protein containing the RING finger (aa 8 to 46) and the acidic region (aa 71 to 84) was necessary but not sufficient for activation of all classes of EHV-1 promoters, (iii) the RING finger was absolutely essential for activation of EHV-1 promoters, since deletion of the entire RING finger motif (aa 8 to 46) or a portion of it (aa 19 to 30) completely abrogated the ability of these mutants to activate any promoter tested, (iv) the acidic region contributed to the ability of the EICP0 protein to activate the early and gamma1 late promoters, and deletion of the acidic region enhanced the ability of this mutant to activate the IE promoter, (v) the carboxy terminus (aa 325 to 419), which is rich in glutamine residues, was dispensable for the EICP0 trans-activation function, (vi) a motif resembling a nuclear localization signal (aa 289 to 293) was unnecessary for the EICP0 protein to trans-activate promoters of any temporal class, and (vii) the EICP0 protein was phosphorylated during infection, and deletion of the serine-rich region (aa 210 to 217), a potential site for phosphorylation, reduced by more than 70% the ability of the EICP0 protein to activate the gamma2 late class of promoters.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10627530      PMCID: PMC111454          DOI: 10.1128/jvi.74.3.1200-1208.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  The gamma2 late glycoprotein K promoter of equine herpesvirus 1 is differentially regulated by the IE and EICP0 proteins.

Authors:  S K Kim; D E Bowles; D J O'callaghan
Journal:  Virology       Date:  1999-04-10       Impact factor: 3.616

2.  Characterization and mapping of equine herpesvirus type 1 immediate early, early, and late transcripts.

Authors:  W L Gray; R P Baumann; A T Robertson; D J O'Callaghan; J Staczek
Journal:  Virus Res       Date:  1987-09       Impact factor: 3.303

3.  Mutational analysis of the sequence encoding ICP0 from herpes simplex virus type 1.

Authors:  J X Chen; X X Zhu; S Silverstein
Journal:  Virology       Date:  1991-01       Impact factor: 3.616

Review 4.  Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections.

Authors:  G P Allen; J T Bryans
Journal:  Prog Vet Microbiol Immunol       Date:  1986

5.  Regulation of equine herpesvirus type 1 gene expression: characterization of immediate early, early, and late transcription.

Authors:  W L Gray; R P Baumann; A T Robertson; G B Caughman; D J O'Callaghan; J Staczek
Journal:  Virology       Date:  1987-05       Impact factor: 3.616

6.  Activities of herpes simplex virus type 1 (HSV-1) ICP4 genes specifying nonsense peptides.

Authors:  N A DeLuca; P A Schaffer
Journal:  Nucleic Acids Res       Date:  1987-06-11       Impact factor: 16.971

7.  The products of herpes simplex virus type 1 (HSV-1) immediate early genes 1, 2 and 3 can activate HSV-1 gene expression in trans.

Authors:  R D Everett
Journal:  J Gen Virol       Date:  1986-11       Impact factor: 3.891

8.  DNA sequence and comparative analyses of the equine herpesvirus type 1 immediate early gene.

Authors:  F J Grundy; R P Baumann; D J O'Callaghan
Journal:  Virology       Date:  1989-09       Impact factor: 3.616

9.  Characterization of equine herpesvirus type 1 immediate early proteins.

Authors:  G B Caughman; A T Robertson; W L Gray; D C Sullivan; D J O'Callaghan
Journal:  Virology       Date:  1988-04       Impact factor: 3.616

10.  A detailed mutational analysis of Vmw110, a trans-acting transcriptional activator encoded by herpes simplex virus type 1.

Authors:  R D Everett
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

View more
  22 in total

1.  Mapping the sequences that mediate interaction of the equine herpesvirus 1 immediate-early protein and human TFIIB.

Authors:  H K Jang; R A Albrecht; K A Buczynski; S K Kim; W A Derbigny; D J O'Callaghan
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Characterization of cis-acting elements required for autorepression of the equine herpesvirus 1 IE gene.

Authors:  Seongman Kim; Gan Dai; Dennis J O'Callaghan; Seong Kee Kim
Journal:  Virus Res       Date:  2012-01-14       Impact factor: 3.303

3.  The infected cell protein 0 encoded by bovine herpesvirus 1 (bICP0) associates with interferon regulatory factor 7 and consequently inhibits beta interferon promoter activity.

Authors:  Kazima Saira; You Zhou; Clinton Jones
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

4.  Cytoplasmic localized infected cell protein 0 (bICP0) encoded by bovine herpesvirus 1 inhibits β interferon promoter activity and reduces IRF3 (interferon response factor 3) protein levels.

Authors:  Leticia Frizzo da Silva; Natasha Gaudreault; Clinton Jones
Journal:  Virus Res       Date:  2011-06-12       Impact factor: 3.303

5.  The unique IR2 protein of equine herpesvirus 1 negatively regulates viral gene expression.

Authors:  Seong K Kim; Byung C Ahn; Randy A Albrecht; Dennis J O'Callaghan
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  The EHV-1 UL4 protein that tempers viral gene expression interacts with cellular transcription factors.

Authors:  Yunfei Zhang; Robert A Charvat; Seong K Kim; Dennis J O'Callaghan
Journal:  Virology       Date:  2013-11-21       Impact factor: 3.616

7.  The bovine herpesvirus 1 immediate-early protein (bICP0) associates with histone deacetylase 1 to activate transcription.

Authors:  Y Zhang; C Jones
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  A negative regulatory element (base pairs -204 to -177) of the EICP0 promoter of equine herpesvirus 1 abolishes the EICP0 protein's trans-activation of its own promoter.

Authors:  Seong K Kim; Randy A Albrecht; Dennis J O'Callaghan
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  Interaction of the equine herpesvirus 1 EICP0 protein with the immediate-early (IE) protein, TFIIB, and TBP may mediate the antagonism between the IE and EICP0 proteins.

Authors:  Seong K Kim; Hyung K Jang; Randy A Albrecht; Wilbert A Derbigny; Yunfei Zhang; Dennis J O'Callaghan
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  The zinc RING finger of bovine herpesvirus 1-encoded bICP0 protein is crucial for viral replication and virulence.

Authors:  Kazima Saira; Shafiqul Chowdhury; Natasha Gaudreault; Leticia da Silva; Gail Henderson; Alan Doster; Clinton Jones
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.